Patents Examined by Enrique D. Longton
  • Patent number: 6420152
    Abstract: The gene for Streptococcus pyogenes DNase B has been cloned and vectors incorporating the cloned DNA have been used to transform Escherichia coli, allowing efficient and rapid production of the DNase in E. coli without the necessity of growing large quantities of S. pyogenes. The enzyme can be produced with a leader peptide at its amino terminus. An improved method for the purification of naturally occurring S. pyogenes DNase B enzyme is also provided. The DNase B enzyme produced, either by purification of naturally occurring enzyme or by recombinant DNA techniques, can be used to generate antibodies and can also be used in immunochemical assays to detect the presence of anti-DNase B antibodies in serum as a marker of infection by S. pyogenes.
    Type: Grant
    Filed: February 24, 1995
    Date of Patent: July 16, 2002
    Assignee: Beckman Instruments, Inc.
    Inventors: Craig W Adams, Patty P. Y. Pang, C. Marina Belei
  • Patent number: 6297215
    Abstract: A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO:1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO:2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
    Type: Grant
    Filed: May 7, 1999
    Date of Patent: October 2, 2001
    Assignee: The University of British Columbia
    Inventors: Robert E. W. Hancock, Nedra Karunaratne
  • Patent number: 6268171
    Abstract: The invention relates to recombinant gene sequences for synthesizing a protein having the biological activity of the PilC protein. Furthermore, the invention relates to DNA recombinant methods for the production of proteins having the biological activity of the PilC protein as well as the tools of molecular biology needed therein. Besides, the invention relates to proteins having the biological activity of the PilC protein and its antibodies. Further embodiments of the invention are pharmaceutical compositions with a content of the mentioned proteins or antibodies. Preferably, these pharmaceutical compositions serve as vaccines for the immunization against pathogenic bacteria bearing type 4 pili. The invention also relates to kits for the detection of bacteria bearing type 4 pili or antibodies directed against them containing the mentioned proteins or antibodies. Finally, the invention relates to cellular receptors for bacteria bearing type 4 pili and analogues thereof.
    Type: Grant
    Filed: June 28, 1996
    Date of Patent: July 31, 2001
    Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.
    Inventors: Thomas Franz Ferdinand Meyer, Thomas Rudel, Roland Richard Ryll, Ina Bärbel Scheuerpflug
  • ERA
    Patent number: 6248556
    Abstract: The invention provides ERA polypeptides and DNA (RNA) encoding ERA polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing ERA polypeptide for the protection against infection, particularly bacterial infections.
    Type: Grant
    Filed: June 19, 1997
    Date of Patent: June 19, 2001
    Assignee: SmithKline Beecham Corporation
    Inventors: Michael Terence Black, Martin Karl Russel Burnham, John Edward Hodgson, David Justin Charles Knowles, Richard O Nicholas, Julie M Pratt, Raymond Winfield Reichard, Martin Rosenberg, Judith M Ward
  • Patent number: 6207411
    Abstract: The present invention relates to a novel anti-microbial agent, more particularly, a novel bacteriocin with nisin-like properties. The bacteriocin is designated lacticin 3147 and has the following properties: a molecular weight of approximately 2.8 kDa; inhibiting activity against lactococci, lactobacilli, enterococci, bacilli, leuconostocs, pediococci, clostridia, staphylococci and streptococci; sensitivity to the proteases trypsin, alpha-chymotrypsin, proteinase K and pronase E but not pepsin; heat-stability; activity at acid pH; and the capability of inhibiting nisin-producing bacterial strains.
    Type: Grant
    Filed: April 13, 1998
    Date of Patent: March 27, 2001
    Assignee: Teagasc
    Inventors: Reynolds Paul Ross, Mary Clare Rea, Marie Philippa Ryan, Colin Hill
  • Patent number: 6204035
    Abstract: A protein preparation that mediates Ca+2 transbilayer movement of phospholipid is disclosed. Additionally, a modified or mutated protein preparation, wherein the protein has a reduced ability to mediate transbilayer movement, is disclosed. In a preferred form of the invention, the protein has been modified such that post-translational modification can no longer occur.
    Type: Grant
    Filed: October 10, 1997
    Date of Patent: March 20, 2001
    Assignee: The Blood Center Research Foundation
    Inventors: Therese Wiedmer, Peter J. Sims
  • Patent number: 6194166
    Abstract: The invention is directed to isolated DNAs having nucleic acid sequences which encode proteins which regulate aureobasidin sensitivity. Also disclosed are recombinant plasmids containing the DNAs, transformants containing the plasmids, and methods of producing the proteins.
    Type: Grant
    Filed: September 20, 1996
    Date of Patent: February 27, 2001
    Assignee: Takara Shuzo Co., Ltd.
    Inventors: Takashi Okado, Kazutoh Takesako, Ikunoshin Kato
  • Patent number: 6180380
    Abstract: The invention relates to a PLK protein, which is characterized in that it comprises (a) the amino acid sequence shown in SEQ ID No: 1 or (b) variants of the sequence from (a).
    Type: Grant
    Filed: November 23, 1998
    Date of Patent: January 30, 2001
    Assignee: Bayer Aktiengesellschaft
    Inventors: Klaus Strebhardt, Helga R{umlaut over (u)}bsamen-Waigmann, Uwe Holtrich
  • Patent number: 6177542
    Abstract: The present invention provides peptides having specificity for fibronectin-binding and vitronectin-binding integrins, and in particular for &agr;5&bgr;1 integrin. These peptides are characterized by having the ability to interfere with extracellular matrix protein binding to integrins; to block attachment of cells expressing these integrins to extracellular matrix proteins; and to promote cell attachment when coated onto a surface.
    Type: Grant
    Filed: August 29, 1997
    Date of Patent: January 23, 2001
    Assignee: The Burnham Institute
    Inventors: Erkki Ruoslahti, Erkki Koivunen
  • Patent number: 6143518
    Abstract: Expression plasmids comprising a nucleic acid sequence of interest controlled by a T7 bacteriophage promoter and a stabilizing region comprising all or part of the par region of the RP4 plasmid or a derivative thereof. The invention also concerns the use of said plasmids in the production of recombinant products.
    Type: Grant
    Filed: March 12, 1997
    Date of Patent: November 7, 2000
    Assignee: Rhone-Poulenc Rorer SA
    Inventors: Beatrice Cameron, Joel Crouzet
  • Patent number: 6127523
    Abstract: The present invention relates to novel collagens and polynucleotide sequences encoding these novel proteins. The present invention further relates to specific collagens and derivatives, specifically .alpha.3(IX) collagen and recombinant trimeric type IX collagen protein.
    Type: Grant
    Filed: May 6, 1998
    Date of Patent: October 3, 2000
    Assignee: UAB Research Foundation
    Inventors: Randolph G. Brewton, Richard Mayne
  • Patent number: 6121426
    Abstract: This invention provides an imaging agent which comprises a polypeptide labeled with an imageable marker, such polypeptide having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin. The invention further provides a method wherein the imaging agent is used for imaging a fibrin-containing substance, i.e., a thrombus or atherosclerotic plaque. Further provided are plasmids for expression of polypeptides having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin, hosts containing these plasmids, methods of producing the polypeptides, methods of treatment using the polypeptides, and methods of recovering, refolding and reoxidizing the polypeptides.
    Type: Grant
    Filed: August 11, 1997
    Date of Patent: September 19, 2000
    Assignee: Bio-Technology General Corp.
    Inventors: Tikva Vogel, Avigdor Levanon, Moshe Werber, Rachel Guy, Amos Panet
  • Patent number: 6103510
    Abstract: The invention provides a novel phospholipase A.sub.2 enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.
    Type: Grant
    Filed: March 20, 1998
    Date of Patent: August 15, 2000
    Assignee: Eli Lilly and Company
    Inventors: Ruth Maria Kramer, Richard Todd Pickard, John David Sharp, Beth Ann Strifler
  • Patent number: 6100076
    Abstract: The present invention describes the identification, purification, recombinant production and characterization of novel O-fucosyltransferase enzymes.
    Type: Grant
    Filed: November 26, 1997
    Date of Patent: August 8, 2000
    Assignee: Genentech, Inc.
    Inventors: Yang Wang, Michael W. Spellman
  • Patent number: 6090577
    Abstract: The invention provides a human disease associated acidic protein and polynucleotides which identify and encode DAAP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of DAAP.
    Type: Grant
    Filed: May 22, 1997
    Date of Patent: July 18, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Surya K. Goli
  • Patent number: 6087160
    Abstract: This invention relates to genes involved in regulating programmed cell death, the proteins encoded by such genes and methods for controlling programmed cell death by regulating the activity of the cell death gene products.
    Type: Grant
    Filed: January 4, 1995
    Date of Patent: July 11, 2000
    Assignee: The General Hospital Corporation
    Inventors: Junying Yuan, Masayuki Miura
  • Patent number: 6087333
    Abstract: The invention provides a human disease associated acidic protein and polynucleotides which identify and encode DAAP. The invention also provides expression vectors, host cells. agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of DAAP.
    Type: Grant
    Filed: August 24, 1999
    Date of Patent: July 11, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Surya K. Goli
  • Patent number: 6083735
    Abstract: This invention relates to proteins encoded by the cell death genes that are involved in regulating programmed cell death. In particular, the invention describes the cell death protein Ich-1 (Caspase-2) and its alternative splicing products Ich-1.sub.L and Ich-1.sub.S. Methods for controlling programmed cell death by regulating the activity of the cell death gene products are also described.
    Type: Grant
    Filed: June 10, 1994
    Date of Patent: July 4, 2000
    Assignee: The General Hospital Corporation
    Inventors: Junying Yuan, Masayuki Miura
  • Patent number: 6084069
    Abstract: The present invention relates, in general, to autotaxin. In particular, the present invention relates to a DNA segment encoding autotaxin; recombinant DNA molecules containing the DNA segment; cells containing the recombinant DNA molecule; a method of producing autotaxin; antibodies to autotaxin; and identification of functional domains in autotaxin.
    Type: Grant
    Filed: November 24, 1997
    Date of Patent: July 4, 2000
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Mary Stracke, Lance Liotta, Elliott Schiffmann, Henry Krutzch, Jun Murata
  • Patent number: 6080841
    Abstract: The present invention provides a polynucleotide which identifies and encodes a novel human induced tumor protein (HITP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding HITP. The invention also provides for the production and use of substantially purified HITP in pharmaceutical compositions to force differentiation and to stop cell division in cancerous cells. The invention also describes diagnostic assays which utilize the polynucleotide to hybridize with the transcripts encoding HITP and the anti-HITP antibodies which specifically bind to HITP.
    Type: Grant
    Filed: April 9, 1998
    Date of Patent: June 27, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Phillip R. Hawkins